Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (therasphere): Safety, tumor response, and survival

Journal of Vascular and Interventional Radiology

Volumn 16, Issue 12, 2005, Pages 1627-1639

  Salem, Riad ^a,e   Lewandowski, Robert J ^a   Atassi, Bassel ^a   Gordon, Stuart C ^b   Gates, Vanessa L ^a   Barakat, Omar ^a   Sergie, Ziad ^d   Wong, Ching Yee O ^c   Thurston, Kenneth G ^e  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b Henry Ford Health Systems   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Radiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; MICROSPHERE; THERASPHERE; YTTRIUM 90; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BLOOD FLOWMETRY; CANCER LOCALIZATION; CANCER SURVIVAL; CHILD PUGH SCORING SYSTEM; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER RESECTION; LYMPHOCYTOPENIA; MALE; OKUDA SCORING SYSTEM; PRIORITY JOURNAL; RIGOR; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL TIME; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; INTERVENTIONAL RADIOLOGY; LIVER TUMOR; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RADIATION DOSE; SURVIVAL; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICROSPHERES; PROSPECTIVE STUDIES; RADIOGRAPHY, INTERVENTIONAL; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 33646102404     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000184594.01661.81     Document Type: Article

References (47)

1. Seeff LB. Introduction: the burden of hepatocellular carcinoma. Gastroenterology 2004; 127(suppl 5):S1-S4.
2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127(suppl 5):S218-S224.
3. Huang CC, Wu MC, Xu GW, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84:262-264.
4. Soini Y, Virkajarvi N, Raunio H, et al. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 1996; 49:470-473.
5. Stillwagon GB, Order SE, Guse C, et al. 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response. A Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys 1989; 17:1223-1229.
6. Dawson LA, McGinn CJ, Lawrence TS. Conformal chemoradiation for primary and metastatic liver malignancies. Semin Surg Oncol 2003; 21:249-255.
7. Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13(suppl 9):S259-S263.
8. Head HW, Dodd GD. Thermal ablation for hepatocellular carcinoma. Gastroenterology 2004; 127(suppl 5):S167-S178.
9. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127(suppl 5):S179-S188.
10. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of yttrium-90 microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60:1552-1563.
11. Yorke ED, Jackson A, Fox RA, et al. Can current models explain the lack of liver complication in Y-90 microsphere therapy? Clin Cancer Res 1999; 5(suppl 10):3024s-3030s.
12. Russell JL Jr, Carden JL, Herron HL, et al. Dosimetry calculations for yttrium-90 used in the treatment of liver cancer. Endocuriether Hypertherm Oncol 1988; 4:171-186.
13. Salem R, Thurston KG, Carr BI, et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002; 13:S223-S229.
14. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic yttrium-90 microspheres. J Nucl Med 2000; 41:1673-1681.
15. 90Y-microspheres: a risk stratification analysis. J Vasc Interv Radiol 2005; 16:195-203.
16. 90Y-microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16:205-213.
17. Geschwind JFH, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127(suppl):S194-S205.
18. Child CG, Turcotte JD. Surgery and portal hypertension. In: Child CG, ed. The liver and portal hypertension. Philadelphia: WB Saunders, 1964;1950.
19. Pugh R, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
20. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56:918-928.
21. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755.
22. Bruix J, Sherman M, Llovet J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona - 2000 EASL Conference. J Hepatol 2001; 35:421-430.
23. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
24. National Cancer Institute. Common Toxicity Criteria, version 3.0. Bethesda, MD: NCI, 1999. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30- 992.pdf. Accessed July 1, 2005.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
26. Cox DR, Oaks D. Analysis of survival data. London: Chapman & Hall, 1984.
27. Wolfe H. Nonparametric Statistical Methods. New York: John Wiley, 1973; 114-120.
28. Diggle PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford: Clarendon Press, 1994.
29. Hardin JW, Hilbe JM. Generalized Estimating Equations. New York: Chapman & Hall, 2003.
30. Lipsitz SH, Laird NM, Harrington DP. Generalized estimating equations for correlated binary data: using the odds ratio as a measure of association. Biometrika 1991; 78:153-160.
31. Nowak AK, Chow PKH, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004; 40:1474-1484.
32. Johnson PJ. Hepatocellular carcinoma: Is current therapy really altering outcome? Gut 2002; 51:459-462.
33. Cusnir M, Patt YZ. Novel systemic therapy options for hepatocellular carcinoma. Cancer J 2004; 10:97-103.
34. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
35. Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739.
36. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332:1256-1261.
37. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of I-131 labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161.
38. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003; 97:1042-1050.
39. 90yttrium glass microspheres (TheraSphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10:S107-S110.
40. Wong LL, Tanaka K, Lau L, et al. Pretransplant treatment of hepatocellular carcinoma: Assessment of tumor necrosis in explanted livers. Clin Transplant 2004; 18:227-234.
41. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578-1583.
42. Huo TI, Huang YH, Wu JC, et al. Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. Ann Oncol 2004; 15:775-780.
43. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 11:710-719.
44. Andrews JC, Walker SC, Ackerman RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637-1644.
45. Safaraz M, Kennedy AS, Cao ZJ, et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 2003; 30:199-203.
46. Lopez RR, Pan SH, Hoffman AL, et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002; 137:653-658.
47. Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18:189-195.